Peroxisome proliferator‐activated receptor (PPAR) modulators: Diabetes and beyond*
- 5 October 2001
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 21 (6) , 540-552
- https://doi.org/10.1002/med.1025
Abstract
Peroxisome proliferator‐activated receptors (PPARs) are a class of ligand modulated transcription factors with a prominent role in the regulation of metabolic processes. This report is intended to provide a limited introduction to the PPAR field, sketched with reference to one early series of PPAR ligands. © 2001 John Wiley & Sons, Inc. Med Res Rev, 21, No. 6, 540–552, 2001Keywords
This publication has 63 references indexed in Scilit:
- Rosiglitazone in the Treatment of Type 2 Diabetes Mellitus: A Critical ReviewClinical Therapeutics, 2001
- Drs. Malinowski and Bolesta reply:Clinical Therapeutics, 2001
- Alterations of Peroxisome Proliferator-activated Receptor δ Activity Affect Fatty Acid-controlled Adipose DifferentiationPublished by Elsevier ,2000
- PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancerTrends in Pharmacological Sciences, 2000
- Activation of PPARδ alters lipid metabolism in db/db miceFEBS Letters, 2000
- Ligand-induced stabilization of PPARγ monitored by NMR spectroscopy: implications for nuclear receptor activationJournal of Molecular Biology, 2000
- Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferatorsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000
- TroglitazoneDrugs, 1999
- Differential activity of rosiglitazone enantiomers at PPARγBioorganic & Medicinal Chemistry Letters, 1998
- Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte DifferentiationNew England Journal of Medicine, 1998